Information Journal Paper
APA:
Copy. (2018). Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 51(3), 498-502. SID. https://sid.ir/paper/778179/en
Vancouver:
Copy. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS[Internet]. 2018;51(3):498-502. Available from: https://sid.ir/paper/778179/en
IEEE:
Copy, “Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes,” INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 51, no. 3, pp. 498–502, 2018, [Online]. Available: https://sid.ir/paper/778179/en